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Abstract
Background: To compare visual function and structural improvements in pseudophakic eyes with diabetic macular
oedema (DMO) treated with the 0.19mg Fluocinolone Acetonide (FAc) intravitreal implant (IluvienTM) in a ‘real
world’ setting.
Methods: A single centre retrospective evaluation of patients with DMO unresponsive to conventional
treatment treated with the FAc implant according to UK guidelines. Primary efficacy endpoint was best
corrected visual acuity (BCVA); secondary endpoints included optical coherence tomography evaluations of
the macula (a) central retinal and (b) peak macular thickness collected at annual time points. Primary safety
endpoint was new rise in IOP >27mmHg or glaucoma surgery. Patients with <1 year follow-up were
excluded.
Results: Twenty-nine eyes were included, with mean(SD) follow up of 792(270) days. Improvement in BCVA
and reduction in macular oedema was noted at all timepoints. Mean improvement in BCVA from baseline
was 6 ETDRS letters at year 1(n=29), 6.5L at year 2(n=22) and 11L at year 3(n=6). Mean central retinal
thickness at baseline was 451 microns, 337 microns at year 1, 342 microns at year 2 and 314 microns at year
3. Two eyes required IOP-lowering drops post implant. Supplementary treatment for persistence or recurrence
of DMO was necessary in 18 eyes over the total study period of 3 years with mean time to supplementary
treatment being 12 months.
Conclusions: Our evaluation of the 0.19mg FAc implant delivered in a real-world setting, provides additional
evidence that it is effective and safe in the treatment of patients with DMO, and can provide sustained
benefit for patients with previously refractory disease.
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Background
Worldwide 422 million people have diabetes [1]. A third
of these people have diabetic retinopathy (DR) and of
these a further third have vision threatening DR includ-
ing diabetic macular oedema (DMO) [2]. In developed
countries, DMO is a leading cause of blindness in the
working population [3]. DMO occurs due to impairment
of the blood retinal barrier and increased vascular per-
meability caused by anatomical and biochemical changes
including pericyte loss, endothelial cell dysfunction and
increased pro-inflammatory changes [4]. Vascular endo-
thelial growth factor has a major role in these mecha-
nisms, however the role of anti-oxidants, inflammatory
agents and angiogenesis has also been shown [5–7].
For many years laser treatment was the mainstay treat-
ment for DMO, at times supplemented by short acting
corticosteroid injections (peri/intra-ocular triamcino-
lone). In more recent years the role of laser has been
largely replaced by the use of anti-vascular endothelial
growth factor (VEGF) agents (notably bevacizumab,
ranibizumab and aflibercept) [8]. A significant propor-
tion of patients with DMO are however unresponsive to
anti-VEGF agents. Gonzalez et al found that 39.7% pa-
tients treated with anti-VEGF had minimal response of
<5 letter gain in best corrected visual acuity (BCVA)
after 3 months [9]. This ‘minimal response’ at 3 months
was associated with worse long-term BCVA (52 weeks
and 156 weeks), which may provide a simple method of
identifying sub-optimal DMO responders.
Fluocinolone acetonide [FAc] 0.19mg was approved by
NICE in 2013 as a treatment option for pseudophakic
patients with chronic DMO that are refractory to other
therapies, such as laser and anti-VEGF [10]. The main
source of evidence for its efficacy was the Fluocinolone
Acetonide in Diabetic Macular Edema (FAME) A and B
randomized clinical trials which showed clinical effect-
iveness of 36 months duration [11, 12]. Although ‘real-
world’ data is now emerging, it is still largely limited to
the first two years after implantation [8]. The aim of this
study was to evaluate the longer-term clinical effective-
ness and safety of the FAc implant in patients with
DMO treated in the context of a single tertiary centre in
the UK.
Methods
This is a single centre retrospective evaluation of the use
of the 0.19mg FAc implant (IluvienTM) in patients with
DMO unresponsive to conventional treatment. This
evaluation was approved by and registered with the rele-
vant NHS trust (University Hospitals Birmingham NHS
Foundation Trust). Patients were assessed for treatment
with the FAc implant as guided by NICE (UK) Technol-
ogy Appraisal (TA301) which restricts its use to refrac-
tory DMO in pseudophakic patients. Refractory DMO
was determined by clinician and assessed as an inad-
equate response to conventional therapy (laser and/or
anti-VEGF) either no reduction in central retinal thick-
ness or minimal reduction from treatment and a persist-
ence in macula oedema of >250um. Post-FAc
implantation, patients continued to be seen regularly to
evaluate efficacy and safety, and to monitor associated
retinopathy and other ocular disease. For the purposes
of this evaluation, the inclusion criteria was all patients
at our centre who had been treated with the FAc implant
for refractory DMO and for whom there was a mini-
mum of one year follow-up. Data was extracted an-
onymously from the electronic medical record
(Medisoft) in March 2017. The primary efficacy end-
point was best corrected visual acuity (BCVA). Absolute
BCVA was evaluated in LogMAR but for presentation of
change in BCVA this was converted to number of letters
to enable direct comparison to the FAME study [13].
Secondary efficacy endpoints included spectral domain
optical coherence tomography (SD-OCT) evaluation of
the central retinal thickness and peak macular thickness
as per the HeyexTM software from Heidelberg Engineer-
ing (Heidelberg, Germany), proportion of cases requiring
‘top-up’ treatment, and time from baseline for ‘top-up’
treatment.
The primary safety endpoint was new rise in IOP over
27mmHg or glaucoma surgery. Evaluation was carried
out at annual time-points up to 3 years. Patients with
less than 1 year follow-up or who had received treat-
ment for other pathology (e.g. for uveitis) were excluded.
Statistical Analysis
BCVA, mean central retinal thickness and mean peak
macular thickness were evaluated against baseline for
each time-point using student’s unpaired t test for para-
metric data and Mann-Whitney test for non-parametric
data. P-values were calculated with a value of less than
0.05 taken to indicate statistical significance. Statistical
analysis was performed using SPSS version 20.
Results
Demographics
Overall 37 eyes (33 patients) were treated with the FAc
implant between January 2014 and March 2016. Four
eyes (4 patients) were excluded due to being treated for
non-DMO diagnosis and a further 4 eyes (2 patients)
were excluded due to having less than 1 year follow-up.
Of the 29 eyes (27 patients) included, mean age of the
patients was 69.1 (range, 44-90) with an equal distribu-
tion of gender (13 females, 14 males) and laterality of
eye treated (Right eye 17, left eye 12). Mean baseline
BCVA was 0.77 and 97% were pseudophakic (28 of 29
eyes). Three eyes (2 patients) received the FAc implant
after laser treatment alone due to unsuitability for use of
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anti-VEGF post recent stroke/heart disease. Three pa-
tients (3 eyes) had had previous vitrectomy. Twenty of
29 eyes had a duration of DMO more than 3 years prior
to implant. Full data outcomes were available for 29 eyes
at year 1, 20 at year 2 and 6 at year 3. Mean (SD) dur-
ation of DMO prior to treatment was 2.6 (0.77) years; in
the subset for which 3 year data is available the duration
of DMO was more than 3 years in all cases with mean
(SD) duration 3.2 (0.31) years.
All patients had received either laser and/or anti-
VEGF prior to treatment with the FAc implant (Table 1).
Twenty six eyes had at least 1 prior laser therapy, 17
eyes had at least 1 prior ranibizumab injection, 19 eyes
had at least 1 prior bevacizumab injection and 6 eyes at
least 1 prior treatment with triamcinolone. 10 eyes had
treatment with both ranibizumab and bevacizumab. All
3 eyes unsuitable for anti-VEGF had prior treatment
with triamcinolone injection. Minimum time to FAc im-
plant from prior treatment was 8 weeks.
Efficacy endpoints: Best corrected visual acuity
Mean (SD) BCVA at baseline was 0.77 (0.37) for all 29
eyes. BCVA improved at all time points with mean (SD)
letter gain of 6 (15) at 1 year (p<0.05), 6.5 (15) at 2 years
(p=0.90) and 11 (7) at 3 years (p<0.05) after implantation
(Fig. 1). Of the 6 patients with at least 3 years follow-up,
three eyes (3 patients) had an improvement of 15 letters
or more at 3 years from baseline.
Efficacy endpoints: Retinal thickness
Mean central retinal thickness at baseline was 451 microns,
and mean peak retinal thickness was 488 microns. There
was a reduction in both central and peak retinal thickness
at all time-points relative to baseline (Fig. 1). The mean
(SD) reduction in central retinal and peak thickness was
114 (177) (p<0.001) and 124 (160) (p<0.00001) micrometers
respectively at year 1, 103 (207) (p<0.005) and 104 (114)
(p<0.001) micrometers at year 2, and 65 (162) (p<0.05) and
99 (90) (p<0.05) micrometers at year 3. Of the patients with
at least 3 years follow-up, 50% of eyes (50% of patients)
were clinically dry at 3 years from baseline (p<0.05). Case
examples demonstrating OCT appearances pre- and post-
FAc implant are provided in Fig. 2.
Of the 33 eyes with a clinical diagnosis of DMO treated
with the FAc implant (ie including the four eyes excluded
from the primary follow-up on the basis of less than one
year’s follow-up), 9 eyes (27%) showed no significant im-
provement in macular oedema with no reduction or min-
imal reduction in peak or central thickness at any timepoint.
Safety endpoints
There were 2 eyes (2 patients) with raised intraocular
pressure (IOP) >27mmHg post injection one found at 1
month follow up and one at 6 months follow up. Both
were controlled with drops alone. These cases had estab-
lished raised intraocular pressure (IOP) prior to treatment
with the FAc implant: one had a previous diagnosis of
ocular hypertension (OHT) and one had a previous diag-
nosis of primary open angle glaucoma (POAG) for which
they were under glaucoma specialist follow up and had
been controlled with drops alone. No other ocular or sys-
temic side effects were identified for any patient.
Persistent or recurrence of DMO requiring supplementary
treatment
Supplementary treatment for either persistence of DMO
(treatment failure) or recurrence of DMO (premature
loss of effect) was necessary in 18 eyes. Supplementary
treatment was with one or more of laser (n=4), intravit-
real triamcinolone (n=3) or anti-VEGF agent (aflibercept
n=11; bevacizumab n=4; ranibizumab n=3). No patients
had retreatment with the FAc implant. 10 of 29 (34.5%)
eyes had required supplementary treatment by 1 year, 12
of 20 (60%) eyes by 2 years and 5 of 6 (83.3%) eyes by 3
years. Mean number of extra treatments needed per eye/
year was 2 at year 1, 1.85 at year 2 and 1.66 at year 3.
Mean time until supplementary treatment was 12
months (range 2-22 months), with a mean of 2.6 retreat-
ments (range 1 to 9) during the follow-up period. For the
subset with 3 year follow-up, 5 out of 6 eyes needed supple-
mentary treatment with anti-VEGF or laser. Mean time to
supplementary treatment was 12.8 months in this cohort
(range 10-16 months) with mean number of retreatments
needed from this point being 5. In the supplementary treat-
ment group (n=18), mean BCVA at baseline was 0.71 (64.5
L) with a mean change in BCVA was -0.18 (9 L gain
(p=0.026)) at 1 year, -0.09 (4.5 L gain (p=0.26)) at 2 years,
and -0.22 (11 L gain (p=0.047)) at 3 years.
In the group who did not require supplementary treat-
ment (n=11) during the follow-up period mean BCVA at
baseline was 0.82 (59 L), with a mean change in BCVA of
-0.05 (2.5 L gain (p=0.28)) at 1 year, -0.14 (7 L gain (p=0.18))
at 2 years, and -0.3 (15 L gain) at 3 years (Fig. 3).
FAc implant in vitrectomised eyes
Three eyes had had previous vitrectomy prior to FAc im-
plant, with one year data being available for 3 eyes, and
Table 1 Prior therapies, number treated and mean number of
treatments for all eyes





Focal/grid macula laser 10 1.15 1-3
Ranibizumab 17 3.94 1-8
Bevacizumab 18 4.32 1-13
Triamcinolone 16 2.31 1-6
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two year data for 1 eye. Mean (SD) BCVA at baseline
was 0.83 (0.06), with a mean change of -0.13 (0.11) (6.5
letter gain (p=0.18)) at 1 year, and -0.13 (0.06) (6.5 letter
gain (p=0.06)) at 2 years. Mean (SD) CRT was 326 (70)
micrometers at baseline, with a mean change of -55.7 mi-
crometers (116) (p=0.31) at 1 year, and -87.7 (62) (p=0.14)
at 2 years. Mean peak macula thickness was 412 (77.2) mi-
crometers thickness at baseline, with a mean change of
-63.7 micrometers (81) (p=0.31) at 1 year and -84 (62)
(p=0.14) at 2 years. Of the three eyes in this group, one re-
quired supplementary treatment at 22 months.
Discussion
Our study provides some of the first ‘real world’ data
through to 3 years follow-up for the effect and safety of
the 0.19 mg FAc implant in patients with DMO. Three
year data for the FAc implant has hitherto been based al-
most exclusively on the pivotal FAME study, which dem-
onstrated a 15 letter gain or more at 36 months in over
a quarter of patients treated with low dose FAc implant
and a reduction of 100 micrometers or more in CRT
[11]. The effect on visual acuity was noted to be more
significant in those with chronic DMO for more than 3
years compared to the cohort with a more recent diag-
nosis [11]. Our findings are in line with results of the
FAME study, with 50% eyes in our series gaining 15
letters or more and being ‘dry’ on OCT analysis at three
years (3 of 6 eligible eyes with three year follow-up data).
All three of these eyes had had a duration of DMO more
than 3 years. Worse outcomes would be expected in our
cohort compared to patients being treated today as pa-
tients may have FAc offered at an earlier stage in DMO,
whereas many patients in our cohort had a duration of
DMO of at least 3 years prior to treatment with FAc im-
plant. A longer duration of DMO and associated disrup-
tion to the retinal architecture is known to affect visual
outcomes [14].
Other ‘real world’ data of the use of the FAc implant is
now emerging. El-Ghrably et al have shown the add-
itional value of treatment with the FAc implant, in pa-
tients initially treated with anti-VEGF as BCVA and
CRT improved and was maintained at 12 months [15].
In our study the effects were maintained at 36 months
in those who responded to the FAc implant. We further
evaluated the need for supplementary treatment over the
3-year period which has not yet been reported in real-
world studies. Thirty four percent of eyes had required
supplementary treatment by 1 year, 60% by 2 years and
83.3% of eyes by 3 years however overall treatments
needed was less than or equal to 2 at each year. None of
our patients needed retreatment with the FAc implant at
3 years. This significantly lowers the retreatment burden
Fig. 1 Improvement in BCVA and reduction in retinal thickness at 1, 2 and 3 years after treatment with FAc implant. Graph (a) showing mean values
for ETDRS letters gained, mean (SD) central retinal thickness (CRT) and peak macular thickness as measured by SD-OCT. Significance at each time-point
was tested against baseline (b)
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when compared to a recent, large, comparative study
of aflibercept, bevacizumab, or ranibizumab which re-
ported that a mean of 9-10 injections were required
to control DMO over 12 months [16]. Reduction of
injection burden is an important benefit of the FAc
implant, as high frequency of intravitreal injections
has been shown to affect quality of life and to in-
crease anxiety and work absences in patients with
DMO [17]. Most patients want fewer injections and
appointments, to achieve the same visual results [17].
Fewer supplementary treatments not only improves
the quality of life of these patients, but also contrib-
utes to the cost efficacy of the FAc implant.
One question regarding the FAc implant is whether
vitrectomised eyes may respond differently. In line with
the study by Meireles et al [18] , we found the FAc im-
plant to be effective in vitrectomised eyes. Of the three
eyes in our series that had had previous vitrectomies,
only one eye needed further treatment during the
follow-up, and this was at 1.8 years, compared to the
mean supplementary treatment time of 1 year.
The major concerns with the FAc implant are cataract
and glaucoma. Cataract occurred in 82-89% of phakic
patients by 3 years after implantation of the FAc implant
[11] which has led to the NICE (UK) guidelines which
restrict its usage to pseudophakic patients with DMO. In
our study 97% of eyes were pseudophakic as per the
NICE recommendations. Modern cataract surgery is
however extremely successful and safe, and thus it may
be argued that phakic status should not be a complete
bar to treatment if the FAc implant was shown to be
otherwise safe and effective. A recent cost analysis has
shown that single treatment with the FAc implant is
more cost effective than multiple injections of ranibizu-
mab even after allowing for the additional cost of cata-
ract surgery [19]. Although less common than cataract,
the greater concern is elevated intraocular pressure
(IOP). In FAME, three year data noted an adverse event
Fig. 2 SD-OCT images pre- and post-FAc implant in patients with chronic DMO. a. Right eye of 42 year old male with type 1 diabetes and a 4
year history of DMO treated with previous anti-VEGF, triamcinolone and grid laser. DMO (a1) resolved by 8 months (a2) b. Left vitrectomised eye
of a patient with 5 year history of DMO. Treated with anti-VEGF, triamcinolone and grid laser. DMO (b1) resolved by 5 months (b2). c. Right eye of
45 year old male chronic non attender with type 1 diabetes and a 1.2 year history of DMO treated with anti-VEGF. DMO (c1) resolved by 3 months
(c2). d. Left vitrectomised eye of 53 year old female with type 1 diabetes and 1 year history of DMO treated with anti-VEGF. DMO (d1) resolved by 5
months (d2)
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of elevated IOP of 37% in the standard FAc group (vs
12% in the sham group) and incisional glaucoma surgery
being required in 4.8% (vs 0.5% of the sham group). It is
interesting to note that our reported adverse events were
significantly lower than reported in FAME, although this
may in part be due to the relatively smaller number of
eyes achieving the three year time-point. In our study
only 2 out of 33 eyes were reported to have raised IOP
and both of these had a prior history of raised IOP.
These patients were successfully treated with drops and
did not need surgery. Although Alfaqwi et al have previ-
ously reported that there is no additional risk with the
FAc implant in patients with well controlled OHT at 12
months [20], further studies are required to evaluate the
effect on IOP long-term in patients with OHT and/or
POAG.
The primary limitation of our study is its retrospective
design and limited numbers, although all data was col-
lected prospectively and recorded on our electronic
medical record and imaging database. Use of an elec-
tronic medical record platform is also a limitation as
limited data is routinely recorded via this platform and
therefore limits analysis of crucial factors such as HbA1c
and type of diabetes. Use of EMR is however widespread
now and is an important method of continuous medical
record and source for clinical information in various
studies. An additional limitation is that there is variable
follow-up, with a diminishing number of patients across
the later time-points reflecting the ongoing recruitment
to treatment with the FAc implant; this seemed prefera-
ble to either limiting the analysis to only that subset
which had achieved three years follow-up, or to prema-
turely censor the follow-up period. Finally we recognize
that this is a relatively small study, reflecting its single
site nature. The results of the study are however in line
with the FAME trials and does provide ‘real world’ sup-
port to those results.
Conclusions
In summary our study is the first to report ‘real world’
clinical outcomes of the therapeutic effects and risk pro-
file of the FAc implant in pseudophakic patients with
chronic DMO through to 36 months in UK. There was
an improvement in mean VA at all time-points with a
mean overall improvement in vision of 8.5 letters at 3
years (p<0.05), associated with a mean reduction in CRT
and peak macula thickness. Although three year data
was only available for a subset of our patients, 50% of
these patients had a 15 letter or more improvement at
this time-point, broadly comparable to the 34% with a
similar benefit in the FAME study [10]. It should be
noted however that almost two-thirds of the eyes in our
Fig. 3 (Supplementary) Improvement in BCVA and reduction in retinal thickness at 1, 2 and 3 years after treatment with FAc implant in those
patients who did not require supplementary treatment. Graph (a) showing mean values for ETDRS letters gained, mean (SD) central retinal thickness
(CRT) and peak macular thickness as measured by SD-OCT. Significance at each time-point was tested against baseline (b)
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series required further treatment within three years. The
FAc implant appears to provide clinical benefit in pseu-
dophakic patients with chronic DMO that are insuffi-
ciently responsive to first line therapies, with a
significant proportion of patients benefitting for up to 3
years as shown in the FAME trials [11, 12]. The FAc im-
plant has the added benefit of less frequent visits and
fewer injections. It should be considered in all pseudo-
phakic patients with refractive DMO, or considered after
laser alone in patients where anti-VEGF is contraindi-
cated. Our outcomes support the findings of the FAME
trial that the FAc implant can be safely used in such pa-
tients and significantly improve BCVA and reduce mac-
ula oedema whilst reducing the overall cost and burden
of treatment in this sight-threatening disease.
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